SCHEMBL22435009

SCHEMBL22435009

Nc1ncnn2c([C@H]3CC[C@@H](CN4CC(F)(F)CC45CCNCC5)O3)ccc12

nearest known ligand 0.49

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 6/20 0.49
▸ WDR77 Q9BQA1 3/20 0.33
▸ ACVRL1 P37023 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22434978 0.88 PRMT5 (0.38) PRMT5WDR77
SCHEMBL23584601 0.87 PRMT5 (0.37) PRMT5
SCHEMBL23584466 0.85 PRMT5 (0.36) PRMT5
SCHEMBL23584677 0.85 PRMT5 (0.47) PRMT5WDR77ACVRL1
SCHEMBL22435029 0.85 PRMT5 (0.36) PRMT5
SCHEMBL23584803 0.84 PRMT5 (0.51) PRMT5WDR77
SCHEMBL23584538 0.83 PRMT5 (0.35) PRMT5
SCHEMBL19344183 0.82 PRMT5 (0.61) PRMT5WDR77
SCHEMBL22434806 0.81 CNR2 (0.37) PRMT5
SCHEMBL23584795 0.81 CNR2 (0.37) PRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3426664-B1 SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2021-06-30 — — EP disclosed
US-20200289539-A1 NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2020-09-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200289539-A1 NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 PRMT5 1/4885WDR77 133/4885ACVRL1 3137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback